Semax and the FDA 503A Decision: The ACTH-Fragment Neuropeptide FDA Declined to List

The Short Answer

At the July 24, 2026 PCAC meeting, FDA proposed that Semax (free base) and Semax acetate not be added to the 503A Bulks List. The nomination (later withdrawn, with FDA proceeding) covered uses including analgesia, ADHD, and nootropic/cognitive enhancement. FDA found insufficient characterization and human safety information.

What Semax Is

Semax is a heptapeptide (seven amino acids) derived from a fragment of adrenocorticotropic hormone (ACTH 4–10), developed in Russia, where it is a registered drug available as an intranasal product. It is widely marketed in the US through wellness, concierge, and regenerative-medicine channels for a broad list of neurological and cognitive uses. See our Semax peptide page for background.

Characterization: "Not Well-Characterized"

FDA deemed both forms not well-characterized, citing inconsistent naming conventions (INN, IUPAC, USAN) and the absence, in the public literature, of substance-specific quality-control attributes — impurities, aggregates, bacterial endotoxin, and microbial bioburden testing — along with a lack of certificate-of-analysis data.

Historical Use: Broad Marketing, Unclear Compounding

Semax injection and intranasal products are widely marketed in the US for anxiety, depression, memory/attention, stroke and ischemic events, nerve regeneration, ADHD, opioid withdrawal, and several neurodegenerative conditions. Semax is a registered drug in Russia, but FDA found the extent of its use in US compounding unclear.

Effectiveness and a Notable Pharmacology Signal

Nonclinically, semax is pleiotropic — through poorly understood mechanisms it has shown neuroprotective, neurotrophic, anticoagulant/antithrombotic, analgesic, and antidepressant/anxiolytic-like effects in rodents. FDA highlighted one concerning finding: in mice, semax potentiated amphetamine-induced dopamine release, a signal relevant to abuse-related pharmacology. As with the others, the human effectiveness evidence for the nominated uses was not sufficient to support listing.

Safety: No Human PK, No Data for the Proposed Route

FDA concluded there is insufficient clinical information to characterize the safety profile of semax. It found no human pharmacokinetic studies by any route, and no safety data for the proposed subcutaneous route — the only route discussed in the clinical literature was intranasal, and it was often unclear which substance form was used. Injectable use raises the familiar unaddressed immunogenicity concern.

What It Means for Physicians

Semax was not FDA-approved in the US and remains so. Its status as a registered drug in Russia does not confer US approval or a compounding pathway. See the pillar overview and confirm access with your 503A compounding partner.

Key Takeaways

• FDA is proposing that Semax (free base and acetate) not join the 503A Bulks List.
• Human PK and SC-route safety data are absent; clinical literature covered only intranasal use.
• FDA flagged that semax potentiated amphetamine-induced dopamine release in mice — an abuse-relevant signal.
• Russian drug registration does not translate to US approval or a 503A compounding pathway.

Frequently Asked Questions

Is semax banned by the FDA?
No. FDA is proposing that semax not be added to the 503A Bulks List — an advisory-committee proposal, not a final rule. Semax is not FDA-approved in the US.

What is semax derived from?
It is a heptapeptide based on a fragment of adrenocorticotropic hormone (ACTH 4–10).

Semax is a registered drug in Russia — doesn't that count?
No. Registration in Russia does not confer US FDA approval and does not create a lawful 503A compounding pathway in the United States.

Why did FDA mention dopamine and amphetamine?
In mice, semax potentiated amphetamine-induced dopamine release. FDA noted this as a concerning pharmacology signal relevant to abuse potential.

Track Live FDA Peptide Status

Regulatory status changes as PCAC hearings and FDA determinations roll out. Bookmark our FDA Peptide Status Tracker 2026 for the latest category and PCAC updates on every peptide.